Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients
- PMID: 30522347
- DOI: 10.1177/1060028018817904
Ribociclib in HR+/HER2- Advanced or Metastatic Breast Cancer Patients
Abstract
Objective: To review the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of ribociclib (LEE011, Kisqali) in hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer.
Data sources: A PubMed search was performed using the terms 'Ribociclib', 'Kisqali', and 'LEE011' between May 2018 and November 2018. References of published articles and reviews were also assessed for additional information.
Study selection and data extraction: English-language preclinical and clinical studies on the chemistry, pharmacology, pharmacokinetics, safety, and efficacy of ribociclib were evaluated.
Data synthesis: Ribociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, is Food and Drug Administration (FDA) approved in combination with endocrine therapy for treatment of HR+/HER2- advanced or metastatic breast cancer in premenopausal/perimenopausal and postmenopausal women. Three phase III trials have evaluated ribociclib in combination with endocrine therapy, including letrozole, anastrozole, tamoxifen, and fulvestrant. These studies found that ribociclib 600 mg/d, 21 days on, 7 days off, leads to a significantly greater median progression-free survival (PFS), ranging from 8 to 13 months. Ribociclib is well tolerated in elderly patients, maintains health-related quality of life, and significantly reduces pain scores. The dose-limiting toxicities found in phase I studies were neutropenia, thrombocytopenia, and QTc prolongation. Common adverse effects seen in phase III trials include neutropenia, leukopenia, nausea, diarrhea, vomiting, and fatigue. Relevance to Patient Care and Clinical Practice: Literature on the safety and efficacy of ribociclib as well as its place in therapy in comparison to other FDA-approved CDK4/6 inhibitors for breast cancer is discussed.
Conclusions: Ribociclib, when added to endocrine therapy, significantly improves PFS and has manageable toxicity in premenopausal/perimenopausal and postmenopausal women with HR+/HER2- advanced breast cancer.
Keywords: CDK4/6; HER2−; HR+; breast cancer; metastatic breast cancer; ribociclib.
Similar articles
-
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24. Lancet Oncol. 2018. PMID: 29804902 Clinical Trial.
-
Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.Expert Rev Anticancer Ther. 2018 Mar;18(3):201-213. doi: 10.1080/14737140.2018.1435275. Epub 2018 Feb 19. Expert Rev Anticancer Ther. 2018. PMID: 29457921 Review.
-
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.Clin Cancer Res. 2018 Jul 1;24(13):2999-3004. doi: 10.1158/1078-0432.CCR-17-2369. Epub 2018 Feb 7. Clin Cancer Res. 2018. PMID: 29437768
-
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.Breast Cancer Res Treat. 2018 Feb;167(3):659-669. doi: 10.1007/s10549-017-4523-y. Epub 2017 Oct 22. Breast Cancer Res Treat. 2018. PMID: 29058175 Free PMC article. Clinical Trial.
-
Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.Expert Rev Clin Pharmacol. 2017 Nov;10(11):1169-1176. doi: 10.1080/17512433.2017.1376653. Epub 2017 Sep 18. Expert Rev Clin Pharmacol. 2017. PMID: 28875723 Review.
Cited by
-
Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice.Heliyon. 2024 Jan 17;10(2):e24559. doi: 10.1016/j.heliyon.2024.e24559. eCollection 2024 Jan 30. Heliyon. 2024. PMID: 38298714 Free PMC article. Review.
-
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.Mol Cancer. 2023 Jul 6;22(1):105. doi: 10.1186/s12943-023-01805-y. Mol Cancer. 2023. PMID: 37415164 Free PMC article. Review.
-
Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of CDK4/6 Inhibition.Int J Mol Sci. 2023 May 18;24(10):8939. doi: 10.3390/ijms24108939. Int J Mol Sci. 2023. PMID: 37240281 Free PMC article. Review.
-
Role of protein phosphorylation in cell signaling, disease, and the intervention therapy.MedComm (2020). 2022 Nov 3;3(4):e175. doi: 10.1002/mco2.175. eCollection 2022 Dec. MedComm (2020). 2022. PMID: 36349142 Free PMC article. Review.
-
Ribociclib-induced Vitiligo: a Case Report.Dermatol Pract Concept. 2022 Apr 1;12(2):e2022045. doi: 10.5826/dpc.1202a45. eCollection 2022 May. Dermatol Pract Concept. 2022. PMID: 35646430 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous